VivoSeq
Oncology

Mycosis Fungoides and Sézary Syndrome

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Mycosis Fungoides and Sézary Syndrome is an early-stage landscape with 0 programs across 1 company. The most active players are Kyowa Kirin Pharmaceutical Development Ltd.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kyowa Kirin Pharmaceutical Development Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

Prospective Research Based Observational Study of Poteligeo® Experience in the Real World in Adult Patients With Mycosis Fungoides and Sézary Syndrome
Completed·KKyowa Kirin Pharmaceutical Development Ltd·N/A·NCT05455931·73 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)